BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vargatef: Phase II data

In a double-blind Phase II trial in 84 patients, maintenance therapy with Vargatef achieved a 15.6% PFS rate after 9 months vs. 2.9% for placebo. The trial was not powered for direct comparison to placebo. Vargatef demonstrated...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >